Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative Pathway
Open accessThe DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.
Abstract
HIF-1 alpha is a normally labile proangiogenic transcription factor that is stabilized and activated in hypoxia. Although the von Hippel Lindau (VHL) gene product, the ubiquitin ligase responsible for regulating HIF-1 alpha protein levels, efficiently targets HIF-1 alpha for rapid proteasome-dependent degradation under normoxia, HIF-1 alpha is resistant to the destabilizing effects of VHL under hypoxia. HIF-1 alpha also associates with the molecular chaperone Hsp90. To examine the role of Hsp90 in HIF-1 alpha function, we used renal carcinoma cell (RCC) lines that lack functional VHL and express stable HIF-1 alpha protein under normoxia. Geldanamycin (GA), an Hsp90 antagonist, promoted efficient ubiquitination and proteasome-mediated degradation of HIF-1 alpha in RCC in both normoxia and hypoxia. Furthermore, HIF-1 alpha point mutations that block VHL association did not protect HIF-1 alpha from GA-induced destabilization. Hsp90 antagonists also inhibited HIF-1 alpha transcriptional activity and dramatically reduced both hypoxia-induced accumulation of VEGF mRNA and hypoxia-dependent angiogenic activity. These findings demonstrate that disruption of Hsp90 function 1) promotes HIF-1 alpha degradation via a novel, oxygen-independent E3 ubiquitin ligase and 2) diminishes HIF-1 alpha transcriptional activity. Existence of an Hsp90-dependent pathway for elimination of HIF-1 alpha predicts that Hsp90 antagonists may be hypoxic cell sensitizers and possess antiangiogenic activity in vivo, thus extending the utility of these drugs as therapeutic anticancer agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, HSP90 inhibitors and histone acetylase inhibitors promote HIFα degradation in a pVHL-independent manner (Isaacs et al., 2002; Kong et al., 2006).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Isaacs et al., 2002
In the citing paper
“It was reported that inhibitors of Hsp90 such as geldanamycin (GA) could nullify HIF-1α levels regardless of the availability of oxygen42.”
From HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) · cites this paper as [42]
In the citing paper
“GA can induce proteasomal degradation of HIF-1α in a VHL-independent manner both under normoxic and hypoxic conditions (Isaacs et al., 2002).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Isaacs et al., 2002
In the citing paper
“Heat shock protein 90 (HSP90) stabilizes HIF-1α under hypoxia and in tumors, and pharmacological inhibition of HSP90 promotes HIF-1α destabilization [183].”
From HIF inhibition: Current strategies and clinical challenges (2026) · cites this paper as [183]
Citations
Cites
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
Semenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Research works printed but not linked: 18
- Wiesener, 2001, Cancer Res., 61, 5215
- Zhong, 1999, Cancer Res., 59, 5830
- Birner, 2000, Cancer Res., 60, 4693
- Akakura, 2001, Cancer Res., 61, 6548
- Griffiths, 2002, Cancer Res., 62, 688
- Takahashi, 1994, Cancer Res., 54, 4233
- Wizigmann-Voos, 1995, Cancer Res., 55, 1358
- Whitesell, 1992, Cancer Res., 52, 1721
- Shaknovich, 1992, Mol. Cell. Biol., 12, 5059
- Hostein, 2001, Cancer Res., 61, 4003
- Nimmanapalli, 2001, Cancer Res., 61, 1799
- An, 2000, Cell Growth Differ., 11, 355
- Bonvini, 2002, Cancer Res., 62, 1559
- Adams, 1999, Cancer Res., 59, 2615
- Semenza, 1992, Mol. Cell. Biol., 12, 5447
- Hockel, 1999, Cancer Res., 59, 4525
- Mabjeesh, 2002, Cancer Res., 62, 2478
- Kruger, 2001, Clin. Cancer Res., 7, 1867
Cited by
Items 401–500 of 673
Targeting HSP70 chaperones by rhein sensitizes liver cancer to artemisinin derivatives
Wang, J., Zhang, J. C., Guo, Z., Hua, H. M., Zhang, H., Liu, Y., & Jiang, Y. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155156 · Cited by 29
Boovanahalli, S. K., Jin, X., Jin, Y., Kim, J. H., Đạt, N. T., Hong, Y., Lee, J. H., Jung, S., Lee, K., & Lee, J. J. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.09.005 · Cited by 31
Nomura, T., Yamasaki, M., Hirai, K., Inoue, T., Sato, R., Matsuura, K., Moriyama, M., Sato, F., & Mimata, H. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-27 · Cited by 31
“In contrast, tumor hypoxia is progressively associated with increased AR activity, reduced oxidative defense, genomic instability, and apoptosis resistance, and it may be associated with the transition to androgen independence in prostate cancer [31,32].”
BackgroundProtein kinase CK2 inhibition is associated with the destabilization of HIF-1α in human cancer cells
Guerra, B., Rasmussen, T., Schnitzler, A., Jensen, H. H., Boldyreff, B., Miyata, Y., Marcussen, N., Niefind, K., & Issinger, O. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.026 · Cited by 35
Protein kinase D2: a versatile player in cancer biology
Azoitei, N., Cobbaut, M., Becher, A., Lint, J. V., & Seufferlein, T. T. W. (2017) · Oncogene · doi:10.1038/s41388-017-0052-8 · Cited by 30
Hyperbaric oxygen influences chronic wound healing – a cellular level review
Růžička, J., Dejmek, J., Bolek, L., Beneš, J., & Kuncová, J. (2021) · Physiological Research · doi:10.33549/physiolres.934822 · Cited by 34
Xiong, L., Zhao, T., Huang, X. H., Liu, Z., Zhao, H. Y., Li, M., Wu, L., Shu, H., Zhu, L., & Fan, M. (2008) · Cell Stress and Chaperones · doi:10.1007/s12192-008-0071-z · Cited by 29
Ring-truncated deguelin derivatives as potent Hypoxia Inducible Factor-1α (HIF-1α) inhibitors
Kim, H. S., Hong, M., Lee, S.-C., Lee, H., Suh, Y., Oh, D., Seo, J. H., Choi, H., Kim, J. Y., Kim, K.-W., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.09.033 · Cited by 29
Esfandiary, A., Taherian‐Esfahani, Z., Do, A. A., Mirfakhraie, R., Shirzad, ., Ghafouri‐Fard, S., & Motevaseli, E. (2016) · PubMed Central · doi:10.22074/cellj.2016.4319 · Cited by 37
Dimethyl fumarate inhibits the expression and function of hypoxia-inducible factor-1α (HIF-1α)
Zhao, G., Liu, Y., Fang, J., Chen, Y., Li, H., & Gao, K. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.062 · Cited by 33
HIF gene expression in cancer therapy
Chan, D. A., Krieg, A. J., Turcotte, S., & Giaccia, A. J. (2007) · Methods in Enzymology · doi:10.1016/s0076-6879(07)35016-7 · Cited by 26
Yang, F., Cai, J., Zhan, H., Situ, J., Li, W., Mao, Y., & Luo, Y. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/6724810 · Cited by 35
“In contrast with RACK1, the binding of HSP90 to HIF-1α stabilizes HIF-1α causing HIF-1α accumulation [36].”
BackgroundSong, Y. J., Salbu, B., Teien, H., Heier, L. S., Rosseland, B. O., Høgåsen, T., & Tollefsen, K. E. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-694 · Cited by 29
“Key DEGs in this pathway promoting the hydroxylation (P4HB), ubiquitination (P53, HSP90AB1, NQO1, UBE2) and transcriptional regulation (SUMO1) of HIF-α were induced by U, suggesting that salmon may have suffered from U-caused hypoxia [36-42].”
BackgroundWoldemichael, G. M., Vasselli, J. R., Gardella, R. S., McKee, T. C., Linehan, W. M., & McMahon, J. B. (2006) · SLAS DISCOVERY · doi:10.1177/1087057106289234 · Cited by 28
Complex role of the HIF system in cardiovascular biology
Czibik, G. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0646-x · Cited by 31
Heat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?
Isaacs, J. S. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.569 · Cited by 26
Self-citationRecent Insights into Roles of Hypoxia-Inducible Factors in Retinal Diseases
Lee, D., Tomita, Y., Miwa, Y., Kunimi, H., Nakai, A., Shoda, C., Negishi, K., & Kurihara, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810140 · Cited by 31
“With the notion that HSP90 regulates the VHL-independent HIF-1 α -degradative pathway [60], Jo et al. examined whether HSP90 inhibition-mediated HIF-1 α destabilization could affect retinal neovascularization [61].”
BackgroundPotent Inhibition of HIF1α and p300 Interaction by a Constrained Peptide Derived from CITED2
Qin, X., Chen, H., Tu, L., Ma, Y., Liu, N., Zhang, H., Li, D., Riedl, B., Bierer, D. E., Yin, F., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01043 · Cited by 27
Ligand‐dependent protein interactions of the juvenile hormone receptor captured in real time
Tumova, S., & Jindra, M. (2023) · FEBS Journal · doi:10.1111/febs.16719 · Cited by 26
Detecting Cancer Gene Networks Characterized by Recurrent Genomic Alterations in a Population
Efroni, S., Ben‐Hamo, R., Edmonson, M. N., Greenblum, S. I., Schaefer, C. F., & Buetow, K. H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014437 · Cited by 26
Targeting Heat Shock Protein 90 for the Treatment of Malignant Pheochromocytoma
Giubellino, A., Sourbier, C., Lee, M.-J., Scroggins, B., Bullova, P., Landau, M. S., Ying, W., Neckers, L., Trepel, J. B., & Pacák, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056083 · Cited by 26
Self-citationGenomic Dysregulation in gastric tumors
Janjigian, Y. Y., & Kelsen, D. P. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23263 · Cited by 24
Liu, Y., Steinestel, K., ROUHI, A. M., Armacki, M., Diepold, K., Chiosis, G., Simmet, T., Seufferlein, T. T. W., & Azoitei, N. (2017) · Oncotarget · doi:10.18632/oncotarget.20535 · Cited by 26
“Furthermore, HSP90 inhibitor geldanamycin destabilizes HIF-1α protein, an event that negatively impacts on VEGF mRNA levels and VEGF transcriptional activity [24].”
BackgroundInfluentialBarrese, V., Stott, J. B., Galvão, H. B. F., Aubdool, A. A., Hobbs, A. J., Jepps, T. A., McNeish, A. J., & Greenwood, I. A. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.11116 · Cited by 24
Novel Small Molecule Hsp90/Cdc37 Interface Inhibitors Indirectly Target K-Ras-Signaling
Siddiqui, F. A., Parkkola, H., Vukić, V., Oetken-Lindholm, C., Jaiswal, A., Kiriazis, A., Pavic, K., Aittokallio, T. A., Salminen, T. A., & Abankwa, D. (2021) · Cancers · doi:10.3390/cancers13040927 · Cited by 23
Lipid metabolic reprogramming by hypoxia-inducible factor-1 in the hypoxic tumour microenvironment
Seo, J., Yun, J.-E., Kim, S. J., & Chun, Y. (2022) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-022-02683-x · Cited by 28
Belmonte, M., Hoofd, C., Weng, A. P., & Giambra, V. (2016) · Current Oncology · doi:10.3747/co.23.2806 · Cited by 28
Hypoxia-Directed Drug Strategies to Target the Tumor Microenvironment
Hay, M. P., Hicks, K. O., & Wang, J. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5915-6_6 · Cited by 26
Current management of renal cell carcinoma and targeted therapy.
Canda, A. E., & Kırkalı, Z. (2006) · Urology journal./Urology jornal. · Cited by 24
Geldanamycin-induced degradation of Chk1 is mediated by proteasome
Nomura, M., Nomura, N., & Yamashita, J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.160 · Cited by 28
Choi, D., Cai, E. P., Schroer, S. A., Wang, L., & Woo, M. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2010.207 · Cited by 26
“Interestingly, overexpression of Epo in pancreatic islets was shown to have cytoprotective effects”
BackgroundMolecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets
Rucci, N., Sanità, P., Monache, S. D., Alesse, E., & Angelucci, A. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.335 · Cited by 26
Hypoxia-inducible factors not only regulate but also are myeloid-cell treatment targets
Kling, L., Schreiber, A., Eckardt, K., & Kettritz, R. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.4ri0820-535r · Cited by 25
Zhao, S., Zhou, L., Dicker, D. T., Lev, A., Zhang, S., Ross, E. A., & El‐Deiry, W. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-00150-8 · Cited by 23
DUBs, New Members in the Hypoxia Signaling clUb
Schober, A. S., & Berra, E. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00053 · Cited by 21
Loss-of-function zinc finger mutation in the EGLN1 gene associated with erythrocytosis
Sinnema, M., Song, D., Guan, W., Janssen, J. W. H., van Wijk, R., Navalsky, B. E., Peng, K., Donker, A. E., Stegmann, A. P. A., & Lee, F. S. (2018) · Blood · doi:10.1182/blood-2018-06-854711 · Cited by 24
Curtis, K. K., Wong, W. W., & Ross, H. J. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.05.005 · Cited by 26
Ovarian cancer: emerging molecular-targeted therapies
Sourbier, C. (2012) · Biologics · doi:10.2147/btt.s24155 · Cited by 22
Kong, H., Lee, S., Beebe, K. E., Scroggins, B. T., Gupta, G. N., Lee, M.-J., Jung, Y., Trepel, J. B., & Neckers, L. Μ. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.066514 · Cited by 20
“rapidly degraded by proteasomes after their oxygen-dependent ubiquitination that is dependent on VHL recognition (Isaacs et al., 2002; Brahimi-Horn et al., 2005; Semenza, 2009).”
BackgroundSelf-citationThe loss of NDRG2 expression improves depressive behavior through increased phosphorylation of GSK3β
Ichikawa, T., Nakahata, S., Tamura, T., Manachai, N., & Morishita, K. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.07.012 · Cited by 21
Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis
Lussey‐Lepoutre, C., Buffet, A., Morin, A., Goncalves, J., & Favier, J. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2797-y · Cited by 25
Quercetin mediated reduction of angiogenic markers and chaperones in DLA-induced solid tumours.
Anand, K., Asthana, P., Kumar, A., Ambasta, R. K., & Kumar, P. (2011) · PubMed · Cited by 21
SALIDO, E. C., Timson, D. J., Betancor-Fernández, I., Palomino‐Morales, R., Anoz‐Carbonell, E., Pacheco‐García, J. L., Medina, M., & Pey, A. L. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050747 · Cited by 25
Assist Devices Fail to Reverse Patterns of Fetal Gene Expression Despite β-Blockers
Lowes, B. D., Zolty, R., Shakar, S. F., Brieke, A., Gray, N., Reed, M., Calalb, M. B., Minobe, W. A., Lindenfeld, J., Wolfel, E. E., et al. (2007) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2007.08.003 · Cited by 21
Practical strategies for suppressing hypoxia-inducible factor activity in cancer therapy
McCarty, M. F., Barroso-Aranda, J., & Contreras, F. (2010) · Medical Hypotheses · doi:10.1016/j.mehy.2009.12.022 · Cited by 22
“[140–144].”
Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted Therapies
Roviello, G., Aquino, I. D. G., Vascotto, I. A., Venturi, G., D’Angelo, A., Winchler, C., Guarino, A., Cacioppo, S., Modesti, M., Mela, M. M., et al. (2024) · Genes · doi:10.3390/genes16010006 · Cited by 31
Reactive oxygen and nitrogen species: multifaceted regulators of ovarian activity
Bezdíček, J., Sekaninová, J., Janků, M., Makarevič, A., Luhová, L., Dujíčková, L., & Petřivalský, M. (2025) · Biology of Reproduction · doi:10.1093/biolre/ioaf032 · Cited by 28
HIF-prolyl hydroxylase is a potential molecular target for esculetin-mediated anti-colitic effects
Yum, S., Jeong, S., Lee, S., Kim, W., Nam, J., & Jung, Y. (2015) · Fitoterapia · doi:10.1016/j.fitote.2015.03.013 · Cited by 19
Self-citationTargeting the Mitochondrial Chaperone TRAP1 Alleviates Vascular Pathologies in Ischemic Retinopathy
Kim, S., Yoon, N. G., Im, J. Y., Lee, J. H., Kim, J., Jeon, Y., Choi, Y. J., Lee, J., Uemura, A., Park, D. H., et al. (2023) · Advanced Science · doi:10.1002/advs.202302776 · Cited by 24
Peptidome analysis of cerebrospinal fluid in neonates with hypoxic-ischemic brain damage
Hou, X., Yuan, Z., Wang, X., Cheng, R., Zhou, X., & Qiu, J. (2020) · Molecular Brain · doi:10.1186/s13041-020-00671-9 · Cited by 23
Cardillo, M. R., & Ippoliti, F. (2007) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200702000105 · Cited by 20
Diacetoxyscirpenol as a new anticancer agent to target hypoxia-inducible factor 1
Choi, Y.-J., Shin, H., Chun, Y., Leutou, A. S., Son, B. W., & Park, J. (2016) · Oncotarget · doi:10.18632/oncotarget.11529 · Cited by 20
EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers
Papale, M., Ferretti, E., Battaglia, G., Bellavia, D., Mai, A., & Tafani, M. (2018) · Frontiers in Pediatrics · doi:10.3389/fped.2018.00328 · Cited by 20
Alternative regulation of HIF-1α stability through Phosphorylation on Ser451
Han, H., Saeidi, S., Kim, S., Piao, J., Lim, S., Quispe, Y. N. G., Choi, B. Y., & Surh, Y. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.01.047 · Cited by 22
Yang, Y., Liu, L., Sun, J., Wang, S., Yang, Z., Li, H., Huang, N., & Zhao, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.629543 · Cited by 22
Anti-angiogenic potential of an ethanol extract of Annona atemoya seeds in vitro and in vivo
Yi, J.-M., Park, J.-S., Lee, J. H., Hong, J. T., Bang, O., & Kim, N. S. (2014) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-14-353 · Cited by 19
“HIF-1α, which is a component of a transcriptional complex that induces more than 60 genes required for tumors to adapt to hypoxic stress [31], is extremely labile under normoxia [35].”
BackgroundYum, S., Doh, H.-J., Hong, S., Jeong, S., Kim, D., Park, M., & Jung, Y. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.12.008 · Cited by 20
Self-citationRhee, S. H., Ma, E. L., Lee, Y., Taché, Y., Pothoulakis, C., & Im, E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.678979 · Cited by 21
“However, recent studies indicate that HIF-1 can control VEGF in hypoxia-independent settings as well (10, 49).”
BackgroundExploring the role of mitochondrial UQCRB in angiogenesis using small molecules
Jung, H. J., & Kwon, H. J. (2013) · Molecular BioSystems · doi:10.1039/c3mb25426g · Cited by 19
Zhang, L., Ma, J., Li, Y., Guo, L., Ran, Y., Liu, S.-L., Jiang, C. L., & Zhu, D. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.06.019 · Cited by 19
“…receptor,MyoD,mutant p53 and HIF-1α), kinases (e.g., AKT, ERBB2, C-RAF, B-RAF, v-Src and CDK4), steroid hormone receptors (estrogen and androgen), survivin and telomerase hTERT (Powers and Workman 2006; Isaacs et al. 2002; Sharp et al. 2007), which contribute to the cancer development.”
BackgroundPRDM14 directly interacts with heat shock proteins HSP90α and glucose‐regulated protein 78
Moriya, C., Taniguchi, H., Nagatoishi, S., Igarashi, H., Tsumoto, K., & Imai, K. (2017) · Cancer Science · doi:10.1111/cas.13458 · Cited by 20
Crouch, B. T., Murphy, H., Belonwu, S. A., Martinez, A. F., Gallagher, J., Hall, A. H. S., Soo, M. S., Lee, M., Hughes, P. F., Haystead, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17832-x · Cited by 18
Self-citationOlmos, G., Arenas, M., Bienes, R., Calzada, M. J., Aragonés, J., García-Bermejo, M., Landázuri, M. O., & Lucio-Cazaña, J. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0039-x · Cited by 19
“Thus, under normoxic conditions, HIF-1a expression is modulated by glycogen synthase kinase-3 [11] receptor of activated protein kinase C-1 [12], histone deacetylases [13], heat shock protein 90 [ 14 ], calciumcalpain [15] and cathepsin B [16].”
BackgroundInfluentialPalayoor, S. T., Burgos, M. A., Shoaibi, A., Tofilon, P. J., & Coleman, C. N. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0005 · Cited by 18
“C2 RCC cells overexpressed HIF-1 protein and a small amount of HIF-2 protein under normoxic conditions as a result of nonfunctional VHL (VHL-ve), whereas C2VHL cells stably transfected with wild-type VHL (VHL ve) showed minimal HIF-1 and HIF-2 expression (Fig.”
InfluentialPyrithione-zinc Prevents UVB-induced Epidermal Hyperplasia by Inducing HIF-1α
Cho, Y., Lee, K.-H., & Park, J. (2010) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2010.14.2.91 · Cited by 19
“For example, HSP90 and HSP70 associate with HIF-1α and induce the stabilization and the degradation of HIF-1α, respectively [21,22].”
Background17-AAG: mechanisms of antitumour activity
Konstantinopoulos, P. A., & Papavassiliou, A. G. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.12.1471 · Cited by 18
Huo, X., Yu, Z., Zhao, F. H., Chen, Y., Chen, P., Xing, L., Qiao, Y., Peng, Y., Tian, M., Zhou, M., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.09.023 · Cited by 17
Akinsulie, O. C., Shahzad, S., Ogunleye, S. C., Oladapo, I. P., Joshi, M., Ugwu, C. E., Gbadegoye, J. O., Hassan, F. O., Adeleke, R. A., Akande, Q. A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1224102 · Cited by 19
Hsp90 Regulates the Phosphorylation and Activity of Serum- and Glucocorticoid-regulated Kinase-1
Belova, L., Brickley, D. R., Ky, B., Sharma, S. K., & Conzen, S. D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803289200 · Cited by 20
Requirement of Hsp105 in CoCl 2 -induced HIF-1α accumulation and transcriptional activation
Mikami, H., Saito, Y., Okamoto, N., Kakihana, A., Kuga, T., & Nakayama, Y. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.02.004 · Cited by 20
Salgado, R. M., White, A. C., Schneider, S. M., & Mermier, C. M. (2014) · Physiology Journal · doi:10.1155/2014/121402 · Cited by 20
Advances in high-throughput screening technology for toxicology
Hsu, C. W., Huang, R., Attene‐Ramos, M. S., Austin, C. P., Simeonov, A. M., & Xia, M. (2017) · International Journal of Risk Assessment and Management · doi:10.1504/ijram.2017.082562 · Cited by 18
The role of hypoxia inducible factor-1 in cell metabolism – a possible target in cancer therapy
Aiba, R. S. B., Dimova, E. Y., Görlach, A., & Kietzmann, T. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.4.583 · Cited by 19
“The Hsp90 inhibitor geldanamycin was shown to inhibit hypoxia-induced stabilisation of HIF-1α by promoting its degradation in a VHL-independent manner [182-186].”
BackgroundTurcotte, S., Sutphin, P. D., & Giaccia, A. J. (2008) · Autophagy · doi:10.4161/auto.6785 · Cited by 22
Xu, Y., Gu, Y., Yang, J., Xi, K., Tang, J., Bian, J., Cai, F., & Chen, L. (2021) · Cell Biology International · doi:10.1002/cbin.11574 · Cited by 16
Intrauterine Exposure to Cadmium Reduces HIF-1 DNA-Binding Ability in Rat Fetal Kidneys
Jacobo‐Estrada, T., Cárdenas‐González, M., Santoyo-Sánchez, M. P., Thévenod, F., & Barbier, O. C. (2018) · Toxics · doi:10.3390/toxics6030053 · Cited by 16
Therapeutic Strategies to Block the Hypoxic Response
DiGiacomo, J. W., & Gilkes, D. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_10 · Cited by 17
Quantitative analyses for effects of neddylation on CRL2VHL substrate ubiquitination and degradation
Wang, K., Reichermeier, K. M., & Liu, X. (2021) · Protein Science · doi:10.1002/pro.4176 · Cited by 15
Heat Shock Protein 90: The Cancer Chaperone
Neckers, L. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6401-2_12 · Cited by 18
Self-citationNovel therapies for renal cell carcinoma ? an update
Fishman, M., & Antonia, S. J. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.4.593 · Cited by 20
Vanderstraeten, J., Derradji, H., Sonveaux, P., Colin, I. M., Many, M., & Gérard, A.-C. (2018) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00095.2017 · Cited by 16
Tumor Dormancy and Reactivation: The Role of Heat Shock Proteins
Amissah, H. A., Combs, S. E., & Shevtsov, M. A. (2024) · Cells · doi:10.3390/cells13131087 · Cited by 15
“Correspondingly, HSP90 has been reported as a potent stabilizer of HIF-α for angiogenesis in the normoxic environment [188] of the tumor mass juxtaposed with the hypoxic environment.”
BackgroundModulation of hypoxia-inducible factors (HIF) from an integrative pharmacological perspective
Rodríguez-Jiménez, F. J., & Moreno‐Manzano, V. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0813-4 · Cited by 16
Surgical Management of von Hippel-Lindau Disease: Urologic Considerations
Reed, A. B., & Parekh, D. J. (2008) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2008.08.005 · Cited by 16
Multi-pathway cellular analysis of compound selectivity
Hancock, M. K., Lebakken, C. S., Wang, J., & Bi, K. (2010) · Molecular BioSystems · doi:10.1039/c003669b · Cited by 16
Basson, M. D. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64385-4 · Cited by 15
Ban, H. S., Shimizu, K., Minegishi, H., & Nakamura, H. (2012) · Pure and Applied Chemistry · doi:10.1351/pac-con-11-11-03 · Cited by 16
Suzuki, Y., Kondo, Y., Hara, S., Kimata, R., & Nishimura, T. (2010) · International Journal of Urology · doi:10.1111/j.1442-2042.2010.02450.x · Cited by 15
Myocardial Ischemia: Basic Concepts
Pantos, C. I., Mourouzis, I. S., & Cokkinos, D. V. (2006) · Basic science for the cardiologist · doi:10.1007/0-387-28658-6_2 · Cited by 18
Mechanisms of haemoglobin mass expansion following heat stress
Jenkins, E. J., Edgett, B. A., Hughes, M. G., Tremblay, J. C., & Stembridge, M. R. (2025) · The Journal of Physiology · doi:10.1113/jp288997 · Cited by 15
Using molecular biology to develop drugs for renal cell carcinoma
Cowey, C. L., & Rathmell, W. K. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.3.311 · Cited by 15
[Response to hypoxia. A systemic mechanism based on the control of gene expression].
Caramelo, C. A., Deudero, J. J. P., Castilla, Á., Justo, S., Solís, A. J. D., Neria, F., Peñate, S., & González‐Pacheco, F. R. (2006) · PubMed · Cited by 29
HIF1α-dependent hypoxia response in myeloid cells requires IRE1α
Mawambo, G., Oubaha, M., Ichiyama, Y., Blot, G., Crespo‐Garcia, S., Dejda, A., Binet, F., Diaz-Marin, R., Sawchyn, C., Sergeev, M., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02793-y · Cited by 15
Targeting Tumor Microenvironments for Cancer Prevention and Therapy
Li, V., Reid, D., & Dong, L. (2012) · InTech eBooks · doi:10.5772/28692 · Cited by 17
“It has been shown that the degradation of HIF-1┙ can be induced through inhibiting the chaperone protein HSP90 (Isaacs et al., 2002).”
BackgroundInfluentialMechanisms of sensing and adaptive responses to low oxygen conditions in mammals and yeasts
Trendeleva, T. A., Aliverdieva, D. A., & Zvyagilskaya, R. A. (2014) · Biochemistry (Moscow) · doi:10.1134/s0006297914080033 · Cited by 15
Baranova, K. A., Mironova, V. I., Rybnikova, E. A., & Самойлов, М. О. (2010) · Neurochemical Journal · doi:10.1134/s1819712410010071 · Cited by 13
Urquhart, K., Collins, C., Monte, M. M., Sokołowska, J., Secombes, C. J., & Collet, B. (2016) · Journal of Experimental and Applied Animal Sciences · doi:10.20454/jeaas.2016.1077 · Cited by 13
“Induction of HSP70 has been previously shown in hypoxia conditions (Delaney & Klesius, 2004; Lückstädt et al., 2004), while HSP90 is closely associated with Hypoxia Inducible factor α (Isaacs et al., 2002), though reports on its induction are limited.”
MEK2 Negatively Regulates Lipopolysaccharide-Mediated IL-1β Production through HIF-1α Expression
Talwar, H. S., Bouhamdan, M., Bauerfeld, C. P., Talreja, J., Aoidi, R., Houde, N., Charron, J., & Samavati, L. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801477 · Cited by 14
“In addition to pVHL loss of function, various conditions may lead to HIF-1a accumulation through VHL-independent pathways (16).”
BackgroundGenetically Encoded Tools for Research of Cell Signaling and Metabolism under Brain Hypoxia
Kostyuk, A. I., Kokova, A. D., Podgorny, O. V., Kelmanson, I. V., Fetisova, E. S., Belousov, V. V., & Bilan, D. S. (2020) · Antioxidants · doi:10.3390/antiox9060516 · Cited by 13
“Various factors other than O2 are known to adjust HIF-1α concentration: insulin [125] and IGF-1 [126] are capable of increasing HIF-1α levels via posttranscriptional mechanisms; eIF2α phosphorylation inhibits HIF-1α mRNA translation [127]; RNA-Binding Proteins HuR and PTB act in the opposite manner [128]; and Hsp90 pr…”
BackgroundKong, X., Zhao, L., & Caro, J. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.10.019 · Cited by 13
Metadata
- Authors
- Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M.
- Affiliations
- National Institutes of Health (US)
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-08
- Volume
- 277
- Issue
- 33
- Pages
- 29936-29944
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2022471909
- Cited by
- 663
- References
- 81
- Citations by year
- 2026: 13 · 2025: 12 · 2024: 10 · 2023: 19 · 2022: 22 · 2021: 32 · 2020: 19 · 2019: 20 · 2018: 19 · 2017: 20 · 2016: 22 · 2015: 30 · 2014: 31 · 2013: 27 · 2012: 41
- FWCI
- 13.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6667 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HSP90, HIF-1α, VHL, hypoxia, protein degradation, geldanamycin, E3 ubiquitin ligase, proteasome, renal carcinoma, angiogenesis, vascular endothelial growth factor, anti-angiogenic therapy, hypoxic cell radiosensitizers
- MeSH terms
- Cysteine Endopeptidases, Hydrolysis, Ligases, Multienzyme Complexes, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Down-Regulation, HSP90 Heat-Shock Proteins, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Proteasome Endopeptidase Complex, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.